GO:0002578 negative regulation of antigen processing and presentation: Immune Evasion, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002578 describes any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation.
• It is a biological_process term that sits at the intersection of immunology, cancer biology, and host-pathogen interaction.
• Key molecular players include MHC-I inhibitory receptors, epigenetic enzymes such as CARM1 and EZH2, E3 ubiquitin ligases such as UBE2D3, and lipid metabolic pathways.
• Tumors and pathogens exploit this process to evade CD8+ T cell and CD4+ T cell recognition, making it a major mechanism of immune evasion.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of candidate regulators.
• The term is highly relevant to immuno-oncology, infectious disease, autoimmunity, and vaccine design.
Description
GO:0002578, negative regulation of antigen processing and presentation, is a Gene Ontology biological_process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation. Antigen processing and presentation is the cellular machinery by which peptides are generated from endogenous or exogenous proteins and displayed on MHC class I or MHC class II molecules for recognition by T lymphocytes. Negative regulation of this process is therefore a critical control point that shapes the magnitude and quality of adaptive immune responses. Researchers study GO:0002578 because it is a central mechanism of immune evasion in cancer and infection, and because manipulating it has therapeutic potential in immunotherapy, autoimmunity, and transplantation. The term encompasses diverse molecular strategies, including membrane-associated inhibitory axes that downregulate MHC-I, epigenetic silencing of antigen presentation machinery, ubiquitin-dependent degradation of pathway components, and pathogen-driven interference with Toll-like receptor signaling. Understanding which genes and pathways negatively regulate antigen processing and presentation, and in which cellular contexts, is essential for interpreting single-cell and bulk transcriptomic data, designing CRISPR screens, and developing rational combination immunotherapies.
negative regulation of antigen processing and presentation At A Glance
| GO ID | GO:0002578 |
|---|---|
| GO term | negative regulation of antigen processing and presentation |
| Ontology | biological_process |
| Definition | Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation. |
| Synonyms | down regulation of antigen processing and presentation; down-regulation of antigen processing and presentation; downregulation of antigen processing and presentation; inhibition of antigen processing and presentation |
| Major function | Suppression of peptide generation and MHC-dependent antigen display, limiting T cell activation. |
| Biological context | Immune evasion by tumors and pathogens; peripheral tolerance; resolution of inflammation. |
| Representative regulators | MHC-I inhibitory receptors, CARM1, EZH2, UBE2D3, lipid metabolic enzymes, Toll-like receptor signaling modulators. |
| Disease relevance | Cancer immune evasion, chronic infection, autoimmunity, and vaccine non-responsiveness. |
What Is GO:0002578?
In plain terms, GO:0002578 describes any biological process that reduces, blocks, or shuts down the cellular machinery responsible for preparing antigens and displaying them on MHC molecules. The QuickGO definition states: Any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation. This includes mechanisms that degrade or mislocalize MHC molecules, inhibit peptide generation, disrupt vesicular trafficking of antigen-presenting compartments, or suppress transcription of antigen presentation genes. The term is a biological_process and is not restricted to a single cell type; it applies to tumor cells, infected cells, dendritic cells, macrophages, B cells, and fibroblasts.
Why Is negative regulation of antigen processing and presentation Important in Cell Biology?
Negative regulation of antigen processing and presentation is important because it determines whether the immune system can see a target cell. When this process is pathologically enhanced, tumors and intracellular pathogens escape CD8+ T cell and CD4+ T cell surveillance, leading to disease progression and resistance to immunotherapy. Conversely, when it is dysregulated, excessive antigen presentation can contribute to autoimmunity and chronic inflammation. The term therefore provides a conceptual framework for understanding immune escape, for interpreting antigen-presentation signatures in single-cell and bulk RNA sequencing data, and for designing CRISPR-based experiments that test causality of candidate regulators.
• Defines a core mechanism of tumor immune evasion and resistance to checkpoint blockade.
• Explains how intracellular pathogens such as Mycobacterium tuberculosis interfere with antigen presentation.
• Links epigenetic regulation, including CARM1 and EZH2 activity, to antigen presentation capacity.
• Connects ubiquitin-proteasome and interferon signaling to loss of MHC-I and MHC-II display.
• Provides a framework for interpreting antigen-presenting cell and fibroblast signatures in cancer transcriptomics.
• Informs vaccine design by identifying pathways that limit antigen display.
• Supports discovery of combination therapies that restore antigen presentation and enhance T cell killing.
• Guides CRISPR knockout and overexpression screens for negative regulators of antigen presentation.
• Helps explain antibody feedback regulation of immune responses.
• Highlights lipid metabolism as a modulator of tumor antigen presentation.
What Happens During negative regulation of antigen processing and presentation?
Inhibition of MHC-I surface display
In simple terms: Cells can hide their identity tags from immune cells by pulling MHC-I molecules off the surface or sending them for destruction.
A membrane-associated MHC-I inhibitory axis can reduce surface MHC-I levels and thereby limit CD8+ T cell recognition of cancer cells. This axis represents a direct negative regulatory mechanism within GO:0002578, because it lowers the frequency and extent of antigen presentation at the plasma membrane. Interferon-gamma-driven upregulation of UBE2D3 has also been shown to impair antigen presentation pathways and anti-tumor immunity in pancreatic cancer, providing another route by which MHC-I display is suppressed.
Epigenetic silencing of antigen presentation machinery
In simple terms: Chemical marks on DNA or histones can turn down the genes needed to show antigens to T cells.
The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity, demonstrating that chromatin-modifying enzymes can negatively regulate antigen processing and presentation. Similarly, inhibition of EZH2 augments MHC-I antigen presentation and prevents cancer initiation, indicating that EZH2-mediated epigenetic repression normally restrains antigen display. These findings place epigenetic enzymes upstream of the antigen presentation machinery within GO:0002578.
Ubiquitin-dependent degradation of pathway components
In simple terms: Tagging proteins with ubiquitin can send them to the proteasome for destruction, removing parts needed to present antigens.
IFN-gamma-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer, showing that E3 ubiquitin ligase activity can negatively regulate antigen processing and presentation. This mechanism reduces the availability of components required for peptide loading or MHC trafficking, thereby lowering the rate of antigen display.
Pathogen-driven interference with antigen presentation
In simple terms: Some bacteria and viruses actively block the steps that would otherwise show their proteins to the immune system.
Regulation of antigen presentation by Mycobacterium tuberculosis involves Toll-like receptors, and the pathogen can interfere with these pathways to reduce antigen presentation. This illustrates how pathogens exploit GO:0002578 to establish chronic infection. Antibody feedback regulation also modulates antigen presentation and immune responses, adding a humoral layer of negative control.
Metabolic and lipid-mediated suppression
In simple terms: Changes in fat metabolism inside cells can weaken the machinery that displays antigens.
Lipid metabolism has been linked to tumor antigen presentation, with alterations in lipid pathways contributing to reduced antigen display. This metabolic dimension expands GO:0002578 beyond classical immune signaling and connects it to the tumor microenvironment. Single-cell and bulk RNA sequencing analyses in gastric cancer have identified antigen-presenting and processing fibroblasts, highlighting stromal contributions to antigen presentation regulation.
Key Genes Involved in GO:0002578 negative regulation of antigen processing and presentation
The following genes and proteins have been experimentally implicated in negative regulation of antigen processing and presentation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CARM1 | Epigenetic enzyme that inhibits cross-presenting dendritic cell function | Target for enhancing cancer immunity |
| EZH2 | Histone methyltransferase that represses MHC-I antigen presentation | Inhibition augments antigen presentation and prevents cancer initiation |
| UBE2D3 | E3 ubiquitin ligase upregulated by IFN-gamma that impairs antigen presentation | Linked to anti-tumor immunity failure in pancreatic cancer |
| MHC-I | Antigen display molecule whose surface levels are reduced by inhibitory axes | Central to CD8+ T cell evasion |
| MHC-II | Antigen display molecule for CD4+ T cells, subject to negative regulation | Relevant to antibody feedback and infection |
| TLR2 | Toll-like receptor involved in Mycobacterium tuberculosis regulation of antigen presentation | Host-pathogen interaction studies |
| TLR4 | Toll-like receptor modulating antigen presentation during infection | Innate-adaptive immune crosstalk |
| IFN-gamma | Cytokine that can drive negative regulators such as UBE2D3 | Context-dependent suppression of antigen presentation |
| Lipid metabolic enzymes | Modulate tumor antigen presentation through lipid pathways | Metabolic regulation of immune visibility |
| Antigen-presenting fibroblasts | Stromal cells with antigen processing and presentation signatures | Predictive models in gastric cancer |
| B cells | Participate in antibody feedback regulation of antigen presentation | Humoral immune regulation |
| Dendritic cells | Cross-presenting cells whose function is inhibited by CARM1 | Cancer immunity and vaccine design |
| Proteasome components | Generate peptides for MHC loading; can be indirectly suppressed | Antigen processing machinery |
| TAP transporters | Transport peptides into the ER for MHC-I loading; targets of negative regulation | Antigen presentation pathway |
| ERAP aminopeptidases | Trim peptides for MHC-I; can influence antigen display | Peptide editing |
| Invariant chain (CD74) | Chaperone for MHC-II; its regulation affects antigen presentation | MHC-II pathway |
| Cathepsins | Proteases involved in antigen processing; can be inhibited | Lysosomal antigen processing |
How Is negative regulation of antigen processing and presentation Regulated?
Negative regulation of antigen processing and presentation is controlled at multiple levels. Epigenetic enzymes such as CARM1 and EZH2 repress transcription of antigen presentation genes, and their inhibition restores MHC-I display. Interferon-gamma signaling can paradoxically drive negative regulators such as UBE2D3, which then impair antigen presentation in pancreatic cancer. Toll-like receptor signaling modulates antigen presentation during Mycobacterium tuberculosis infection, illustrating pathogen-driven regulation. Antibody feedback provides a humoral layer of control over antigen presentation and immune responses. Lipid metabolism also influences tumor antigen presentation, linking metabolic state to immune visibility. Together, these layers determine the net rate of antigen processing and presentation in a given cell.
negative regulation of antigen processing and presentation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CARM1 | Cancer immunity and dendritic cell dysfunction | CARM1 knockout dendritic cells in tumor models |
| EZH2 | Cancer initiation and MHC-I downregulation | EZH2 inhibition in cancer cell lines and mouse models |
| UBE2D3 | Pancreatic cancer anti-tumor immunity | UBE2D3 knockout or overexpression in pancreatic cancer cells |
| MHC-I | Cancer immune evasion | MHC-I surface staining and CRISPR knockout of inhibitory axis components |
| TLR2/TLR4 | Mycobacterium tuberculosis infection | Macrophage infection models with TLR knockout |
Cancer immune evasion
Many tumors exploit GO:0002578 to avoid T cell recognition. A membrane-associated MHC-I inhibitory axis reduces surface MHC-I and promotes cancer immune evasion. CARM1 inhibits cross-presenting dendritic cell function in cancer immunity, and its loss enhances anti-tumor responses. EZH2 inhibition augments MHC-I antigen presentation and prevents cancer initiation, showing that epigenetic repression of antigen presentation is a driver of tumorigenesis. IFN-gamma-driven UBE2D3 upregulation impairs antigen presentation and anti-tumor immunity in pancreatic cancer. These findings collectively establish negative regulation of antigen processing and presentation as a central mechanism of cancer immune escape.
Chronic infection
Intracellular pathogens such as Mycobacterium tuberculosis regulate antigen presentation through Toll-like receptors, allowing them to persist despite immune pressure. This pathogen-driven negative regulation of antigen processing and presentation contributes to chronic infection and poor vaccine responses. Antibody feedback regulation also shapes antigen presentation during infection, adding complexity to host-pathogen dynamics.
Autoimmunity and immune regulation
Antibody feedback regulation modulates antigen presentation and can dampen or skew immune responses, with implications for autoimmunity and tolerance. When negative regulation of antigen processing and presentation is impaired, excessive antigen display may contribute to autoimmune activation. Understanding these mechanisms is therefore relevant to both immunodeficiency and autoinflammatory conditions.
Metabolic and stromal contributions
Lipid metabolism influences tumor antigen presentation, linking metabolic reprogramming to immune evasion. In gastric cancer, single-cell and bulk RNA sequencing analyses have identified antigen-presenting and processing fibroblasts and established a predictive model, highlighting stromal contributions to antigen presentation regulation. These findings expand the disease relevance of GO:0002578 beyond tumor cells to the broader microenvironment.
From negative regulation of antigen processing and presentation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene enhance antigen presentation? | CRISPR knockout in tumor cell lines followed by MHC-I flow cytometry |
| Does a specific point mutation in an epigenetic enzyme alter antigen presentation? | Point-mutation knock-in via CRISPR in dendritic cells |
| Does tagging an antigen presentation component reveal its trafficking? | Tagged knock-in of MHC-I or TAP subunits |
| Does overexpression of a negative regulator suppress antigen presentation? | Overexpression of UBE2D3 or EZH2 in cancer cells |
| Which stromal cells regulate antigen presentation in tumors? | Single-cell RNA sequencing of gastric cancer samples |
| Does lipid metabolic perturbation change antigen display? | Lipid pathway knockout or inhibitor treatment in tumor models |
How to Study the negative regulation of antigen processing and presentation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface MHC-I and MHC-II levels | Validation of CRISPR perturbations |
| Single-cell RNA sequencing | Cell-type-specific antigen presentation signatures | Tumor microenvironment mapping |
| Bulk RNA sequencing | Global antigen presentation gene expression | Predictive modeling in cancer |
| CRISPR library screening | Genes whose loss increases antigen presentation | Discovery of negative regulators |
| Proteomics | Protein abundance of antigen presentation machinery | Ubiquitin-mediated degradation studies |
| Immunopeptidomics | Peptides displayed on MHC molecules | Direct measurement of antigen display |
| Imaging | Subcellular localization of MHC and pathway components | Trafficking studies |
| T cell co-culture assays | T cell activation and killing | Functional readout of antigen presentation |
Flow cytometry and MHC surface staining
Flow cytometry is widely used to quantify surface MHC-I and MHC-II levels after genetic perturbation, providing a direct readout of antigen presentation capacity. This method is essential for validating CRISPR knockout or overexpression effects on GO:0002578.
Single-cell and bulk RNA sequencing
Single-cell and bulk RNA sequencing can reveal antigen processing and presentation signatures across cell types, as demonstrated in gastric cancer where antigen-presenting fibroblasts were identified and a predictive model was established. These approaches help map which cells negatively regulate antigen presentation in complex tissues.
CRISPR library screening
Genome-wide CRISPR screens can identify negative regulators of antigen processing and presentation by selecting for cells with increased MHC display or enhanced T cell killing. Such screens are powerful for discovering novel components of GO:0002578.
Proteomics and ubiquitin analysis
Proteomic and ubiquitin-focused analyses can detect degradation of antigen presentation components, as shown for UBE2D3-mediated impairment of antigen presentation pathways. These methods complement transcriptomic data by capturing post-translational regulation.
How CRISPR Can Be Used to Study GO:0002578 negative regulation of antigen processing and presentation
Knockout
CRISPR knockout of candidate negative regulators such as CARM1, EZH2, or UBE2D3 can test whether their loss enhances antigen processing and presentation. Knockout models are typically validated by flow cytometry for MHC surface levels and by T cell co-culture assays.
Point Mutation
Point-mutation knock-in can dissect specific catalytic or interaction residues within epigenetic enzymes or ubiquitin ligases that mediate negative regulation of antigen presentation. Such models distinguish enzymatic activity from scaffolding functions.
Knock-in
Tagged knock-in of MHC-I, TAP, or other antigen presentation components allows tracking of their localization and turnover, revealing how negative regulators alter trafficking. Knock-in of reporter cassettes can also provide sensitive readouts of pathway activity.
Overexpression
Overexpression of suspected negative regulators such as UBE2D3 or EZH2 can suppress antigen presentation and reduce T cell recognition, providing gain-of-function evidence. Overexpression models are useful when endogenous expression is low.
How EDITGENE Supports negative regulation of antigen processing and presentation Research
Researchers studying negative regulation of antigen processing and presentation-related genes often need to determine whether a candidate gene is causally involved in suppressing MHC display or whether it is merely correlated with immune evasion. Rigorous causal testing requires precise genome editing, controlled overexpression, and functional readouts in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of antigen processing and presentation research.
Frequently Asked Questions About negative regulation of antigen processing and presentation
What is GO:0002578?
GO:0002578 is the Gene Ontology biological_process term for negative regulation of antigen processing and presentation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation.
What genes are involved in negative regulation of antigen processing and presentation?
Key genes include CARM1, EZH2, UBE2D3, MHC-I, MHC-II, TLR2, TLR4, and various lipid metabolic enzymes, as reported in cancer and infection studies.
Why is negative regulation of antigen processing and presentation important in cancer?
It allows tumors to hide from T cells by reducing MHC display, contributing to immune evasion and resistance to immunotherapy.
How do tumors suppress antigen presentation?
Tumors use membrane-associated MHC-I inhibitory axes, epigenetic silencing by CARM1 and EZH2, ubiquitin-mediated degradation via UBE2D3, and metabolic reprogramming to reduce antigen display.
What role do epigenetic enzymes play in antigen presentation?
CARM1 inhibits cross-presenting dendritic cell function, and EZH2 represses MHC-I antigen presentation; inhibiting these enzymes restores antigen display.
How can CRISPR be used to study negative regulation of antigen processing and presentation?
CRISPR knockout, point mutation, knock-in, and overexpression models can test whether candidate genes causally suppress MHC display and T cell recognition.
What methods measure antigen presentation?
Flow cytometry for surface MHC, immunopeptidomics for displayed peptides, RNA sequencing for pathway signatures, and T cell co-culture assays for functional readouts are commonly used.
Is negative regulation of antigen processing and presentation relevant to infection?
Yes, pathogens such as Mycobacterium tuberculosis regulate antigen presentation through Toll-like receptors to evade immunity.
What is the role of lipid metabolism in antigen presentation?
Lipid metabolic pathways can modulate tumor antigen presentation, linking metabolic state to immune visibility.
How do fibroblasts contribute to antigen presentation in cancer?
Single-cell and bulk RNA sequencing in gastric cancer identified antigen-presenting and processing fibroblasts and established a predictive model.
Conclusion
GO:0002578, negative regulation of antigen processing and presentation, is a central biological process that governs immune visibility. It integrates epigenetic, ubiquitin-dependent, metabolic, and pathogen-driven mechanisms that reduce MHC display and limit T cell recognition. Understanding its regulators is essential for cancer immunotherapy, infectious disease research, and vaccine design. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with flow cytometry, RNA sequencing, and CRISPR library screening, provide the causal evidence needed to translate these insights into therapeutic strategies.
References
- 1. Chen X et al.. 2023. A membrane-associated MHC-I inhibitory axis for cancer immune evasion.. Cell 186(18):3903-3920.e21 PMID: 37557169
- 2. Zhang C et al.. 2025. Comprehensive analysis of single-cell and bulk RNA sequencing data unveils antigen-presenting and processing fibroblasts and establishes a predictive model in gastric cancer.. Cancer Cell Int 25(1):225 PMID: 40544264
- 3. Zhang X et al.. 2026. The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity.. Science 393(6807):eaea1200 PMID: 42424445
- 4. Heyman B. 2024. Antibody feedback regulation.. Immunol Rev 328(1):126-142 PMID: 39180190
- 5. Wang S et al.. 2025. IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer.. Nat Commun 16(1):10733 PMID: 41315272
- 6. Harding CV et al.. 2010. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors.. Nat Rev Microbiol 8(4):296-307 PMID: 20234378
- 7. Qin H et al.. 2021. Lipid Metabolism and Tumor Antigen Presentation.. Adv Exp Med Biol 1316:169-189 PMID: 33740250
- 8. Ding W et al.. 2025. Prevention of cancer initiation by augmenting MHC-I antigen presentation via EZH2 inhibition.. Oncogene 44(50):4878-4894 PMID: 41286307
